

Alberta Drug Benefit List (ADBL) interim update now available online

Please be advised that the **September 1, 2023** updates to the *Alberta Drug Benefit List (ADBL)* have been posted online at ab.bluecross.ca/dbl/publications.php.

Please refer to the **September 1, 2023** updates for complete listings of products available by special authorization, changes to criteria for coverage, changes to benefit status, added products, new established interchangeable groupings, least cost alternative price changes, products with a price change, discontinued listings and products removed from the *Human Services Drug Benefit Supplement (HSDBS)*.

Please note that the online *interactive Drug Benefit List (iDBL)* at ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application, and as such, contains the most up-to-date information.

Revised Product Identification Numbers (PINs) for continuous glucose monitors for Alberta government-sponsored plans and employee-sponsored group and individual health plans

The following brand-specific PINs for continuous glucose monitors (CGMs) have been revised. Please refer to the table below for affected CGM components with their respective effective dates. Any claim with a date of service *prior* to the effective date should be submitted with the old PIN, claims with a date of service *on or after* the effective date should be submitted with the new PIN.

All Alberta government-sponsored plans and Alberta Blue Cross employer-sponsored group and individual health plan drug programs will continue to utilize brand-specific PINs for CGM components. Pharmacies will need to use the appropriate PIN assigned to the specific brand and CGM component.

Old PIN	New PIN	Effective date	Product description
97799173	00999708	2023/06/27	Dexcom G6 Transmitter
97799174	00999709	2023/06/27	Dexcom G6 Sensor
97799175	00999710	2023/08/17	Guardian Link Transmitter (670g Pump)
97799176	00999712	2023/08/17	Guardian Sensor
97799178	00999711	2023/08/17	Guardian Link Transmitter (770g and 780g Pump)

continued next page

continued from previous page

Product supply shortages addressed for the ADBL

Alberta Blue Cross has confirmed that the shortage for Lorazepam 0.5 mg Sublingual Tablet (DIN 02410745) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **September 13, 2023**. The following grouping was removed from the Critical Supply Product List **August 14, 2023**.

LORAZEPAM

0.5 MG SUBLINGUAL TABLET

00002410745	LORAZEPAM	AAP	\$ 0.0961
00002041456	ATIVAN	PFI	\$ 0.1321

Alberta Blue Cross has confirmed that the shortages for Jamp Pyridostigmine Bromide 60 mg Tablet (DIN 02508362) and Riva-Pyridostigmine 60 mg Tablet (DIN 02495643) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **September 22, 2023**. The following grouping was removed from the Critical Supply Product List **August 22, 2023**.

PYRIDOSTIGMINE BROMIDE

60 MG TABLET

00002508362	JAMP PYRIDOSTIGMINE	JPC	\$ 0.2673
00002495643	RIVA-PYRIDOSTIGMINE	RIV	\$ 0.2673
00000869961	MESTINON	VCL	\$ 0.5235

Alberta Blue Cross has confirmed that the shortages for Jamp Telmisartan-HCT 80 mg/12.5 mg Tablet (DIN 02389940) and Sandoz Telmisartan HCT 80 mg/12.5 mg Tablet (DIN 02393557) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **September 22, 2023**. The following grouping was removed from the Critical Supply Product List **August 23, 2023**.

TELMISARTAN / HYDROCHLOROTHIAZIDE

80 MG / 12.5 MG TABLET

00002419114	ACH-TELMISARTAN HCTZ	AHI	\$ 0.2098
00002456389	AURO-TELMISARTAN HCTZ	AUR	\$ 0.2098
00002389940	JAMP TELMISARTAN-HCT	JPC	\$ 0.2098
00002504146	NRA-TELMISARTAN HCTZ	NRA	\$ 0.2098
00002393557	SANDOZ TELMISARTAN HCT	SDZ	\$ 0.2098
00002390302	TELMISARTAN HCTZ	SIV	\$ 0.2098
00002395355	TELMISARTAN/HCTZ	SNS	\$ 0.2098
00002330288	TEVA-TELMISARTAN HCTZ	TEV	\$ 0.2098
00002244344	MICARDIS PLUS	BOE	\$ 1.2611

continued next page

continued from previous page

Removal of temporary benefit from the ADBL

Due to the shortage of Acetylcysteine 20% Inhalation Solution (DIN 02243098) manufactured by Sandoz Canada Inc. and Acetylcysteine 20% Inhalation Solution USP (DIN 02459906) manufactured by Hikma Pharmaceuticals PLC was added as a temporary benefit for the *Alberta Drug Benefit List*.

Alberta Blue Cross has confirmed that Acetylcysteine 20% Inhalation Solution (DIN 02243098) is now available.

As a result, **Acetylcysteine 20% Inhalation Solution USP (DIN 02459906)** will no longer be considered a temporary benefit for the ADBL **after September 15, 2023**. The above grouping was removed from the Critical Supply Product List **June 8, 2023**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

